65,66 Haughey et al.67 found that the presence of a positive margin after surgery in 7% of their patients raised the risk of death 2.inhibitor bulk 5-fold to 3.0-fold compared with that for patients with negative margins. With TORS, it is relatively easy and less morbid to achieve 5 mm clear surgical margins around a multiplanar en bloc resection in the area of interest, especially Inhibitors,research,lifescience,medical in the oropharynx, without requiring

mandible split or floor of mouth release. Moore et al.68 presented in their study 66 consecutive patients who underwent TORS as the primary treatment for OPSCC and were followed up for a minimum of 2 years. In their series, margins were cleared in 65 of the 66 patients at the time of primary surgery, and 3-year recurrence-free survival was achieved in 92.4% of the patients. In the setting of node-negative disease with no primary site adverse features, the risk of local-regional relapse with observation was less Inhibitors,research,lifescience,medical than 10%.69 Weinstein et al.60 suggested that TORS provides accurate pathologic evaluation when the surgeon verifies clear orientation of the specimen. The high rate of negative margins following TORS has implications for the design and dosing of adjuvant radiotherapy to the primary site. The possible Trichostatin A reduction of dose in adjuvant radiotherapy

is a combination of the reliable margin Inhibitors,research,lifescience,medical status achieved following TORS and the inherent better prognosis of HPV-related SCC.53,70 The role of postoperative radiation in patients with HPV-positive or negative OPSCC is a subject of ongoing research. Reduction of radiation dose and sparing Inhibitors,research,lifescience,medical of chemotherapy has the potential of reducing morbidity and improving short- and long-term QOL.60,71,72 Six reports demonstrated that 8%–37% of patients were spared radiation and 48%–74% of patients did not require chemotherapy Inhibitors,research,lifescience,medical after TORS.20,53,59,62,63,72 This selective approach has the potential to reduce toxicity and the risk

of late complications and reserve treatment modalities for second primary tumors or recurrences.37 Local Control, Disease-specific Survival, and Overall Survival Clinical trials reporting the results of chemoradiation treatment for OPSCC report 3-year disease-free survival and overall survival rates of 42% to 76.5% and 51% to 85%, respectively.27,73 Preliminary data relating to local control, Cilengitide disease-specific survival, and overall survival using upfront TORS are encouraging, with overall survival rates at 1 year exceeding 90% and with 2-year survival rates >80%.20,61,63 Small series reported local failure rates for TORS between 0% and 3% with median follow-up rates ranging from 18 months to 2 years.20,61,63 Regional recurrence rates varied between 2% and 8%,20,61,63 while distant disease was reported in 1%–9% of patients.